ALPMY - Astellas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
12.66
+0.06 (+0.48%)
As of 11:51AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.60
Open12.58
Bid0.00 x 0
Ask0.00 x 0
Day's Range12.58 - 12.66
52 Week Range11.82 - 14.50
Volume14,618
Avg. Volume83,126
Market Cap26.2B
Beta0.38
PE Ratio (TTM)15.18
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-09-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube15 days ago

    ETFs with exposure to Astellas Pharma, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube26 days ago

    ETFs with exposure to Astellas Pharma, Inc. : November 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Reuters27 days ago

    Astellas faces U.S. probe over patient assistance charity support

    Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. In a lawsuit filed on Monday in federal court in Chicago against its insurers, a unit of Japan's Astellas, said the U.S. Justice Department was conducting a joint criminal and civil investigation of the company, its officers and its employees. Astellas US Holdings Inc said it first received a subpoena from the Justice Department in March 2016 in connection with the industry-wide probe and on Oct. 26 entered into an agreement that essentially allows for an extension of the statute of limitations.

  • Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017
    Capital Cube27 days ago

    Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017

    Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US) that have also reported ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Astellas Pharma, Inc. : November 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017
    Capital Cube2 months ago

    Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 1.87 percent and its dividend payout is percent. This compares to ... Read more (Read more...)

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks2 months ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017
    Capital Cube2 months ago

    Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 0.85 percent and its dividend payout is percent. This compares to ... Read more (Read more...)

  • Why Did Pfizer (PFE) Stock Pop Today?
    Zacks3 months ago

    Why Did Pfizer (PFE) Stock Pop Today?

    Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.

  • Reuters3 months ago

    Pfizer, Astellas prostate cancer drug promising in late-stage trial

    Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body.

  • Reuters3 months ago

    UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

    Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease. The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for Pfizer.

  • Capital Cube3 months ago

    ETFs with exposure to Astellas Pharma, Inc. : August 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017
    Capital Cube4 months ago

    Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017

    Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (JNJ-US, MRK-US, PFE-US, AMGN-US and VICL-US) that have also reported ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to Astellas Pharma, Inc. : August 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Astellas Pharma, Inc. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Astellas Pharma, Inc. : June 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q4, 2017 By the Numbers : June 21, 2017
    Capital Cube6 months ago

    Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q4, 2017 By the Numbers : June 21, 2017

    Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (MRK-US, PFE-US, AMGN-US and VICL-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • Seattle Genetics Halts Phase III Study on Leukemia Drug
    Zacks6 months ago

    Seattle Genetics Halts Phase III Study on Leukemia Drug

    Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.

  • Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 31st, 2017 (record date) : By the numbers : April 20, 2017
    Capital Cube8 months ago

    Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 31st, 2017 (record date) : By the numbers : April 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (JNJ-US, MRK-US, PFE-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 1.75 percent and its dividend payout is 28.51 percent. This compares ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to Astellas Pharma, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Money is pouring in to a hot new area of science that could change the way we think about aging
    Business Insider8 months ago

    Money is pouring in to a hot new area of science that could change the way we think about aging

    Venture-capital investors are pouring money into regenerative medicine. According to a report...

  • Capital Cube10 months ago

    ETFs with exposure to Astellas Pharma, Inc. : February 14, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 8, 2017
    Capital Cube10 months ago

    Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 8, 2017

    Categories: Yahoo Finance Get free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Amgen Inc. (JNJ-US, MRK-US, PFE-US and AMGN-US) that have also reported for this period. ... Read more (Read more...)

  • Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 29th, 2016 (record date) : By the numbers : January 30, 2017
    Capital Cube10 months ago

    Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 29th, 2016 (record date) : By the numbers : January 30, 2017

    Categories: Yahoo Finance Get free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (JNJ-US, MRK-US, PFE-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 1.63 percent and its dividend payout is 28.51 percent. This compares ... Read more (Read more...)